A Randomized, Active-Controlled, Double-Blind, Parallel Design, Multi-Center, Phase III Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
Latest Information Update: 26 Aug 2022
At a glance
- Drugs Tertomotide (Primary)
- Indications Benign prostatic hyperplasia
- Focus Registrational; Therapeutic Use
- Sponsors GemVax & KAEL; KAEL-GemVax
Most Recent Events
- 24 Aug 2022 Status changed from active, no longer recruiting to completed.
- 15 Feb 2022 Planned End Date changed from 28 Feb 2021 to 30 Mar 2022.
- 15 Feb 2022 Planned primary completion date changed from 31 Aug 2020 to 30 Mar 2022.